💨 Abstract

Arcturus Therapeutics (ARCT) reported a Q1 loss of $14.1 million or 52 cents per share, beating Wall Street's expected loss of $1.58 per share. The company generated $29.4 million in revenue. Despite surpassing expectations, ARCT's stock has fallen 32% since the start of the year, reaching $11.60

Courtesy: wtop.com

Summarized by Einstein Beta 🤖